Baxter International Inc
BAX: XNYS (USA)
| Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
|---|---|---|---|
| %z# | LOCK|l#Ry | LOCK|kzT |
Baxter Earnings: Hurricane Effects and the Pending Kidney Care Divestiture Overshadow Solid Q3
Narrow-moat Baxter turned in solid third-quarter results, but other events such as Hurricane Helene's effect on its North Carolina manufacturing facility, the pending kidney care division, and guidance for 2024 and 2025 took center stage. At first glance, we intend to keep our $62 fair value estimate intact and still view Baxter's shares as steeply undervalued.
